Stock Analysis
Axsome Therapeutics, Inc. (AXSM) Stock Analysis
Axsome Therapeutics, Inc. (AXSM) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Axsome Therapeutics, Inc. (AXSM) currently has an AIQ Score of 47/100, indicating a bearish setup. Value is the strongest factor at 65/100. Momentum is the weakest current factor at 24/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
AXSM at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $141.69 |
| AIQ Score | 47/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Sell |
| Market Cap | $7.43B |
| P/E Ratio (TTM) | -46.3 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.25 |
| Revenue (Q3 FY2026) | $259.69M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.66 |
| Volume | 973.07K |
| 52-week range | $123.00-$260.19 |
| RSI 14 | 40.79 |
| 50-Day SMA | $171.45 |
| 200-Day SMA | $197.05 |
| Analyst Price Target | $260.14 |
| Next Earnings | Feb 22, 2027 |
AXSMAxsome Therapeutics, Inc.
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum24
- Value65
- Quality57
- Risk resilience57
- Sentiment—
AXSM Stock Analysis Summary
Axsome Therapeutics, Inc. (AXSM) currently has an AIQ Score of 47/100, indicating a bearish setup. Value is the strongest factor at 65/100. Momentum is the weakest current factor at 24/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, AXSM has AIQ Score of 47/100 with Value base of 65/100 and fading Momentum at 24/100. Wait for component alignment before adding exposure.
Value (65/100) leads while Momentum (24/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -1.86% stock move · AXSM classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is AXSM Bullish or Bearish Right Now?
AXSM currently has a bearish overall setup. Value is the strongest factor at 65/100, while Momentum is weakest at 24/100. The current evidence suggests a bearish setup.
- - Analyst target implies +83.60% upside from the latest quote.
- - Momentum is weak at 24/100.
- - Price is -28.09% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (29 vs 8).
Current Consensus
AXSM's Technical Analysis Consensus is currently Sell, with 8 buy, 9 neutral, and 29 sell votes. AXSM's 14-day RSI is 40.79, which places the stock in a weaker momentum range. AXSM's beta is 0.66, indicating lower market sensitivity than the broad market.
What Changed in AXSM?
The largest recent change in AXSM is Value moving down by 1.0 points over the available 7-day comparison window. Value remains the strongest visible factor.
What Would Change the AXSM Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
AXSM Decision Framework
Public evidence layers, setup checks, and risk context for Axsome Therapeutics, Inc..
Axsome Therapeutics, Inc. (AXSM) Stock Analysis
Axsome Therapeutics, Inc. has an AIQ Score of 47/100 in a Bearish regime. Value is strongest at 65/100. Beta is 0.66, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | AXSM is in a Bearish AIQ regime with score 47/100. |
| Signal Conflict | The primary conflict is that value leads at 65/100 while momentum lags at 24/100. |
| Factor Evidence | Momentum 24/100 · Value 65/100 · Quality 57/100 · Risk 57/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Value is the strongest factor at 65/100.
Momentum is 24/100 and RSI (14) is 40.8.
AXSM is in a Bearish regime at 47/100.
Risk factor is 57/100 with beta 0.66 and annual volatility 45.79%.
Current conflict: value leads at 65/100 while momentum lags at 24/100.
AXSM Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
AXSM Fundamentals
AXSM valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
AXSM Technical Analysis
AXSM technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
AXSM Stock Catalysts
Track AXSM earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
AXSM Dividend Analysis
AXSM dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
AXSM Financial Data
AXSM revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
AXSM Risk Analysis
AXSM volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
AXSM Stock News
AXSM stock news, market tone, recent headlines, and catalyst context.
AXSM vs Biotechnology Peers
Current peer cohort: AXSM · BBIO · BCRX · BHVN · BLTE. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| AXSM Current stock | 47/100 | 65/100 | 24/100 | 57/100 | 0.2 | 45.79% | Current |
| BBIO BridgeBio Pharma, Inc. | 64/100 | 55/100 | 69/100 | 62/100 | 0.55 | 44.14% | AXSM vs BBIO |
| BCRX BioCryst Pharmaceuticals, Inc. | 59/100 | 86/100 | 42/100 | 55/100 | 0.36 | 48.06% | AXSM vs BCRX |
| BHVN Biohaven Ltd. | 47/100 | — | 78/100 | 35/100 | 1 | 82.98% | AXSM vs BHVN |
| BLTE Belite Bio, Inc | 74/100 | — | 71/100 | 60/100 | 0.9 | 53.71% | AXSM vs BLTE |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for AXSM: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching AXSM
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for AXSM
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
AXSM Stock FAQ
What is AXSM stock price today?
Axsome Therapeutics, Inc.'s current stock price is $141.69. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is AXSM bullish or bearish right now?
AXSM's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is AXSM's market cap?
AXSM's market cap is $7.43B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is AXSM's current P/E ratio?
AXSM's current P/E ratio is -46.3 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is AXSM's RSI?
AXSM's 14-day RSI is 40.79 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is AXSM above its 50-day and 200-day moving averages?
AXSM is -17.36% from its 50-day SMA and -28.09% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is AXSM's next earnings date?
AXSM's next earnings date is currently listed as Feb 22, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does AXSM pay a dividend?
AXSM's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.